These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Prodrug strategies to overcome poor water solubility. Stella VJ; Nti-Addae KW Adv Drug Deliv Rev; 2007 Jul; 59(7):677-94. PubMed ID: 17628203 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in prodrugs as drug delivery systems. Lin C; Sunkara G; Cannon JB; Ranade V Am J Ther; 2012 Jan; 19(1):33-43. PubMed ID: 21150770 [TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
6. Development of water-soluble prodrugs of the HIV-1 protease inhibitor KNI-727: importance of the conversion time for higher gastrointestinal absorption of prodrugs based on spontaneous chemical cleavage. Sohma Y; Hayashi Y; Ito T; Matsumoto H; Kimura T; Kiso Y J Med Chem; 2003 Sep; 46(19):4124-35. PubMed ID: 12954064 [TBL] [Abstract][Full Text] [Related]
7. [Research of oral prodrugs: opportunities and challenges]. Cao F; Ping QN; Chen J Yao Xue Xue Bao; 2008 Apr; 43(4):343-9. PubMed ID: 18664193 [TBL] [Abstract][Full Text] [Related]
8. Prodrug approaches for CNS delivery. Rautio J; Laine K; Gynther M; Savolainen J AAPS J; 2008; 10(1):92-102. PubMed ID: 18446509 [TBL] [Abstract][Full Text] [Related]
9. What should be considered on design of a colon-specific prodrug? Jung Y; Kim YM Expert Opin Drug Deliv; 2010 Feb; 7(2):245-58. PubMed ID: 20095945 [TBL] [Abstract][Full Text] [Related]
10. Amino acids as promoieties in prodrug design and development. Vig BS; Huttunen KM; Laine K; Rautio J Adv Drug Deliv Rev; 2013 Oct; 65(10):1370-85. PubMed ID: 23099277 [TBL] [Abstract][Full Text] [Related]
11. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Springer CJ; Niculescu-Duvaz I Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927 [TBL] [Abstract][Full Text] [Related]
15. Prodrug research: futile or fertile? Testa B Biochem Pharmacol; 2004 Dec; 68(11):2097-106. PubMed ID: 15498500 [TBL] [Abstract][Full Text] [Related]
16. Prodrug approaches for enhancing the bioavailability of drugs with low solubility. Müller CE Chem Biodivers; 2009 Nov; 6(11):2071-83. PubMed ID: 19937841 [TBL] [Abstract][Full Text] [Related]
17. Membrane transporter/receptor-targeted prodrug design: strategies for human and veterinary drug development. Majumdar S; Duvvuri S; Mitra AK Adv Drug Deliv Rev; 2004 Jun; 56(10):1437-52. PubMed ID: 15191791 [TBL] [Abstract][Full Text] [Related]
18. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors. Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390 [TBL] [Abstract][Full Text] [Related]
19. Do prodrugs deliver? Smith DA Curr Opin Drug Discov Devel; 2007 Sep; 10(5):550-9. PubMed ID: 17786853 [TBL] [Abstract][Full Text] [Related]
20. The expanding role of prodrugs in contemporary drug design and development. Rautio J; Meanwell NA; Di L; Hageman MJ Nat Rev Drug Discov; 2018 Aug; 17(8):559-587. PubMed ID: 29700501 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]